Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors

Inhibition of PARP is a promising therapeutic strategy for homologous recombination–deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Discov
Auteurs principaux: Jaspers, Janneke E., Kersbergen, Ariena, Boon, Ute, Sol, Wendy, van Deemter, Liesbeth, Zander, Serge A., Drost, Rinske, Wientjens, Ellen, Ji, Jiuping, Aly, Amal, Doroshow, James H., Cranston, Aaron, Martin, Niall M.B., Lau, Alan, O’Connor, Mark J., Ganesan, Shridar, Borst, Piet, Jonkers, Jos, Rottenberg, Sven
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7518105/
https://ncbi.nlm.nih.gov/pubmed/23103855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0049
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires